Navigation Links
Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010
Date:9/25/2010

PHILADELPHIA, Sept. 25 /PRNewswire/ -- Today Astellas Pharma US, Inc. ("Astellas") announced results of a Phase IV study showing Lexiscan® (regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies(1). Results were presented during an oral presentation today at the 15th Annual Scientific Sessions of the American Society of Nuclear Cardiology (ASNC) in Philadelphia, Pennsylvania during a session highlighting late-breaker data.

Statistically, regadenoson was found to be not significantly different from placebo in causing a >15% decrease in FEV1 in patients with asthma (p = 0.1451) or COPD (p = 0.5790). Additionally, the change in FEV1 was not affected by baseline disease severity for either the asthma or the COPD subject groups.

Researchers evaluated 999 adult male and female patients (532 asthma and 467 COPD) 18 years of age and older in a multicenter, randomized, double-blind, placebo-controlled study to determine the safety and tolerability of regadenoson in subjects with asthma (FEV1 >60% predicted) or stable COPD (FEV1/FVC <0.70). The subjects had a diagnosis of CAD or risk factors for CAD as determined by a current medical diagnosis of at least two of the following conditions: Type 2 diabetes, hypertension, hypercholesterolemia, current or history of cigarette smoking (minimum 10 pack-years exposure) or obesity Body Mass Index (BMI > 30). A 2:1 randomization to receive a single 10-second IV injection of Lexiscan 0.4 mg (in 5 mL) or placebo was used.

Treatment-emergent adverse events were similar in frequency and severity to those observed in previous studies of regadenoson. Two regadenoson subjects in the COPD group received aminophylline for treatment of adverse events.

About Myocardial Perfus
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel ... soon make it easy and painless for patients to ... treat a wide range of disorders, including cancer, blood ... An emerging biologic drugs market is expected to grow ... these drugs will require a new type of injector ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ... and Pittsburgh markets. Progressive was ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. ... of disease modifying therapeutics for Alzheimer,s disease (AD) ... of its corporate headquarters to Valhalla, ... and expanded lease agreement for additional laboratory space ... which is focused on the development of small ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... 30 Wound Care,Innovations, LLC, a subsidiary of ... today that it will attend and exhibit at,the ... Boston. This,seminar is presented by HMP Communications, the ... and producers of the Symposium on,Advanced Wound Care. ...
... NIH; Findings could benefit,pregnant women worldwide, SEATTLE, ... and Human Development division of the National Institutes ... a $2.9 million grant,for a five-year research project ... known as preeclampsia and migraine., Dr. Williams ...
Cached Medicine Technology:Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R) 2Swedish in Seattle to Study Connections Between Preeclampsia and Migraine 2Swedish in Seattle to Study Connections Between Preeclampsia and Migraine 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... for Installation in United Kingdom, SUNNYVALE, Calif., ... a global leader in the field of radiosurgery,announced ... America (HCA), has purchased its seventh CyberKnife(R),Robotic Radiosurgery ... London,England. This marks HCA,s first non-U.S. CyberKnife System ...
... of heart disease, study finds , , THURSDAY, Oct. 4 (HealthDay ... abnormality in the heart,s left main artery should take special ... brothers and sisters of someone with such problems are 2.5 ... compared to the siblings of patients with heart disease not ...
... Oct 4 Anesiva, Inc.,(Nasdaq: ANSV ) ... for the,investment community to review the company,s launch ... injection system. The briefing will take place on ... Eastern Time in New York City. To,access the ...
... ... diabetes complication, ALEXANDRIA, Va., Oct. 4 Halloween can ... But for some, there is something that is much scarier ... diabetes complication for both men and women.,According to the American ...
... PA) responds to the president,s veto of the ... don,t add up. This President is willing to ... support $35 billion to insure 10 million,of our ... to their,well being. Today,s SCHIP veto proves the ...
... MILWAUKEE, Oct. 3 Could you actually be allergic ... in the workplace,you may suffer from occupational asthma. This ... allergens, chemicals,fumes, gases, dusts or other potentially harmful substances ... Allergy, Asthma & Immunology,(AAAAI). "We estimate that about ...
Cached Medicine News:Health News:Hospital Corporation of America Purchases Seventh CyberKnife(R) System 2Health News:Hospital Corporation of America Purchases Seventh CyberKnife(R) System 3Health News:Hospital Corporation of America Purchases Seventh CyberKnife(R) System 4Health News:Cardiac Artery Trouble Boosts Family Heart Risk 2Health News:Cardiac Artery Trouble Boosts Family Heart Risk 3Health News:Anesiva to Unveil Zingo(TM) Commercialization Plans 2Health News:Diabetes in the Bedroom: Scarier than Halloween? 2Health News:AAAAI: Asthma on the Job 2Health News:AAAAI: Asthma on the Job 3
... onboard rail clamps mount ... tables and stretchers. The ... need for lifting. Easy ... stable surface combined with ...
The DHS Basic Set is available with either self-tapping or non-self-tapping screws. Either instrument set provides complete instrumentation in one graphic case for use with the Universal Implant Set,...
... is a versatile, fully powered orthopaedic and ... traction facilities, a powered centre break and ... versatile too. ,<br.,In fact the RX600 is ... it is for traction procedures. The RX600 ...
... orthopedic trauma procedures. Part of the ... trauma table top provides a complete, ... positioning and provides for skin or ... hip pinnings; femur, supine or lateral ...
Medicine Products: